
ACXP Stock Forecast & Price Target
ACXP Analyst Ratings
Bulls say
Acurx Pharmaceuticals has received positive feedback from both the FDA and EMA, positioning its antibiotic candidate, ibezapolstat (IBZ), favorably ahead of its Phase 3 trial in adult populations, which may enhance investor confidence. Additionally, IBZ has demonstrated encouraging antimicrobial activity and a favorable safety profile, underscoring its potential for addressing critical infections in a clinical setting. The recent endorsement from the Pediatric Committee of the EMA regarding the Pediatric Investigation Plan (PIP) for IBZ further highlights the company's commitment to expanding its therapeutic applications, suggesting a robust development pipeline.
Bears say
Acurx Pharmaceuticals Inc is currently facing significant valuation risks stemming from its clinical-stage status, which inherently limits revenue generation and increases dependency on funding for further development of its antibiotic candidates. The company's focus on a new class of antibiotics, while addressing urgent public health issues, may encounter market entry challenges and regulatory hurdles, which could impede financial advancement. Additionally, the lack of established commercial products leads to uncertainty regarding future profitability, making the stock's outlook more precarious.
This aggregate rating is based on analysts' research of Acurx Pharmaceuticals LLC and is not a guaranteed prediction by Public.com or investment advice.
ACXP Analyst Forecast & Price Prediction
Start investing in ACXP
Order type
Buy in
Order amount
Est. shares
0 shares